The Evolving Landscape of Psychedelic Policy
From Clinical Pathways to Microdosing and Real-World Access
Join leading voices from the Multidisciplinary Association for Psychedelic Studies, New Yorkers for Mental Health Alternatives, and the Microdosing Collective for a grounded, forward-looking conversation on where psychedelic policy stands today, how real-world use is influencing regulation, what equitable access looks like, and what we can learn from past reforms.
Wednesday, June 3rd, 2026
12:30 PM PST | 3:30 PM EST | 8:30 PM GMT
60 minutes with live Q&A
Secure your spot
It’s 2026, and we’re in the middle of psychedelic policy taking shape in real time.
This year alone, federal signals like Trump’s latest executive order are accelerating research and FDA pathways, while states like Colorado and New York push forward very different models for access. At the same time, at least 10 million Americans aren’t waiting. They’re already engaging with psychedelics through practices like microdosing, outside of clinical systems entirely.
So the question isn’t whether things are changing, it’s how all of this actually shapes access. Who it’s for, how it works, what happens when policy meets how people are already using these medicines, and what it would take to build something that reflects both science and cultural reality.
Join leading voices in psychedelic law, policy, and advocacy, including experts from Multidisciplinary Association for Psychedelic Studies (MAPS), New Yorkers for Mental Health Alternatives, and the Microdosing Collective, for a forward-looking conversation on the future of psychedelic and microdosing policy.
What You’ll Learn:
1
Where psychedelic policy stands today, from federal action to state-level momentum
2
Designing policy for real-world use, including microdosing and at-home models
3
What meaningful repair and equity look like as policy evolves
4
Lessons from cannabis legalization, what worked and what to do differently
5
What actually moves policy, from research to storytelling and cultural momentum
Webinar Speakers:
Ismail L Ali, J.D.
Co-Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS)
Allison Hoots, Esq.
Founder and Principal Attorney of Hoots Law Practice PLLC, Head Policy Counsel at New Yorkers for Mental Health Alternatives
Joshua Kappel
Psychedelic Lawyer, Co-Founder of Microdosing Collective, Founding Partner of Vicente LLP
Alli Schaper
Co-Founder of Microdosing Collective Co-Founder of SuperMush, and Host of Into the Multiverse Podcast
Can’t attend live?
Register anyway for free – we’ll send you the recording!